Alan Brennan

List of Publications by Year
in descending order

227 papers	7,156 citations	61984 43 h-index	74163 75 g-index
231 all docs	231 docs citations	231 times ranked	8070 citing authors

#	ARTICLE	IF	CITATIONS
1	Understanding long‑term trends in smoking in England, 1972–2019: an age‑period‑cohort approach. Addiction, 2022, 117, 1392-1403.	3.3	8
2	An integrated dual process simulation model of alcohol use behaviours in individuals, with application to US population-level consumption, 1984–2012. Addictive Behaviors, 2022, 124, 107094.	3.0	4
3	Development of a Web-Based, Guided Self-help, Acceptance and Commitment Therapy–Based Intervention for Weight Loss Maintenance: Evidence-, Theory-, and Person-Based Approach. JMIR Formative Research, 2022, 6, e31801.	1.4	10
4	Expected Value of Sample Information to Guide the Design of Group Sequential Clinical Trials. Medical Decision Making, 2022, 42, 461-473.	2.4	4
5	Investigating the day-to-day impact of hypoglycaemia in adults with type 1 or type 2 diabetes: design and validation protocol of the Hypo-METRICS application. BMJ Open, 2022, 12, e051651.	1.9	13
6	Acceptability and feasibility of an acceptance and commitment therapy-based guided self-help intervention for weight loss maintenance in adults who have previously completed a behavioural weight loss programme: the SWiM feasibility study protocol. BMJ Open, 2022, 12, e058103.	1.9	2
7	Hypo‑METRICS: Hypoglycaemia‑MEasurement, ThResholds and ImpaCtS–A multi‑country clinical study to define the optimal threshold and duration of sensor‑detected hypoglycaemia that impact the experience of hypoglycaemia, quality of life and health economic outcomes: The study protocol. Diabetic Medicine, 2022, 39, .	2.3	11
8	Improving outcomes for women aged 70 years or above with early breast cancer: research programme including a cluster RCT. Programme Grants for Applied Research, 2022, 10, 1-114.	1.0	1
9	Controlled observational study and economic evaluation of the effect of city-centre night-time alcohol intoxication management services on the emergency care system compared with usual care. Emergency Medicine Journal, 2021, 38, 504-510.	1.0	3
10	Quantile regression of tobacco tax pass-through in the UK 2013–2019. How have manufacturers passed through tax changes for different tobacco products?. Tobacco Control, 2021, 30, e27-e32.	3.2	8
11	Developing logic models to inform public health policy outcome evaluation: an example from tobacco control. Journal of Public Health, 2021, 43, 639-646.	1.8	3
12	Bridging the age gap in breast cancer. Impacts of omission of breast cancer surgery in older women with oestrogen receptor positive early breast cancer. A risk stratified analysis of survival outcomes and quality of life. European Journal of Cancer, 2021, 142, 48-62.	2.8	32
13	The effect of alcohol tax changes on retail prices: how do on-trade alcohol retailers pass through tax changes to consumers?. European Journal of Health Economics, 2021, 22, 381-392.	2.8	10
14	Conceptualising changes to tobacco and alcohol policy as affecting a single interlinked system. BMC Public Health, 2021, 21, 17.	2.9	6
15	Using Multi-objective Grammar-Based Genetic Programming to Integrate Multiple Social Theories in Agent-Based Modeling. Lecture Notes in Computer Science, 2021, 12654, 721-733.	1.3	4
16	Do dual purchasers behave differently? An analysis of purchasing data for households that buy both alcohol and tobacco in the United Kingdom. Addiction, 2021, 116, 2538-2547.	3.3	7
17	Bridging the Age Gap in breast cancer: Impact of chemotherapy on quality of life in older women with early breast cancer. European Journal of Cancer, 2021, 144, 269-280.	2.8	37
18	Potential effects of minimum unit pricing at local authority level on alcohol-attributed harms in North West and North East England: a modelling study. Public Health Research, 2021, 9, 1-106.	1.3	7

#	ARTICLE	IF	CITATIONS
19	Bridging the age gap in breast cancer: impact of omission of breast cancer surgery in older women with oestrogen receptor-positive early breast cancer on quality-of-life outcomes. British Journal of Surgery, 2021, 108, 315-325.	0.3	7
20	Alcohol policy and gender: a modelling study estimating gender‐specific effects of alcohol pricing policies. Addiction, 2021, 116, 2372-2384.	3.3	14
21	POS0734â€¦EXTRAPOLATION OF LONG-TERM OUTCOMES IN SYSTEMIC LUPUS ERYTHEMATOSUS: REPLICATING A HOPKINS LUPUS COHORT ANALYSIS WITH THE SYSTEMIC LUPUS INTERNATIONAL COLLABORATING CLINICS (SLICC) INCEPTION COHORT. Annals of the Rheumatic Diseases, 2021, 80, 617.2-618.	0.9	1
22	Bridging The Age Gap: observational cohort study of effects of chemotherapy and trastuzumab on recurrence, survival and quality of life in older women with early breast cancer. British Journal of Cancer, 2021, 125, 209-219.	6.4	26
23	Cost-Effectiveness Modeling of Surgery Plus Adjuvant Endocrine Therapy Versus Primary Endocrine Therapy Alone in UK Women Aged 70 and Over With Early Breast Cancer. Value in Health, 2021, 24, 770-779.	0.3	4
24	Promoting physical activity in a multi-ethnic population at high risk of diabetes: the 48-month PROPELS randomised controlled trial. BMC Medicine, 2021, 19, 130.	5.5	14
25	Commentary on Robinson et al . (2021): Evaluating theories of change for public health policies using computer model discovery methods. Addiction, 2021, 116, 2709-2711.	3.3	1
26	Observational cohort study in older women with early breast cancer: Use of radiation therapy and impact on health-related quality of life and mortality. Radiotherapy and Oncology, 2021, 161, 166-176.	0.6	11
27	Facilitating hospital discharge through housing support: a mixed-methods evaluation of a housing association support service in two UK hospitals. Lancet, The, 2021, 398, S53.	13.7	1
28	Behavioural interventions to promote physical activity in a multiethnic population at high risk of diabetes: PROPELS three-arm RCT. Health Technology Assessment, 2021, 25, 1-190.	2.8	7
29	How Uncertain is the Survival Extrapolation? A Study of the Impact of Different Parametric Survival Models on Extrapolated Uncertainty About Hazard Functions, Lifetime Mean Survival and Cost Effectiveness. Pharmacoeconomics, 2020, 38, 193-204.	3.3	25
30	A Systematic Review of Methods to Predict Weight Trajectories in Health Economic Models of Behavioral Weight-Management Programs: The Potential Role of Psychosocial Factors. Medical Decision Making, 2020, 40, 90-105.	2.4	2
31	The Impact of Including Costs and Outcomes of Dementia in a Health Economic Model to Evaluate Lifestyle Interventions to Prevent Diabetes and Cardiovascular Disease. Medical Decision Making, 2020, 40, 912-923.	2.4	4
32	Multiobjective Genetic Programming Can Improve the Explanatory Capabilities of Mechanism-Based Models of Social Systems. Complexity, 2020, 2020, 1-20.	1.6	13
33	Assessing the contribution of alcohol‐specific causes to socio‐economic inequalities in mortality in England and Wales 2001â€"16. Addiction, 2020, 115, 2268-2279.	3.3	14
34	Effects on alcohol consumption of announcing and implementing revised UK low-risk drinking guidelines: findings from an interrupted time series analysis. Journal of Epidemiology and Community Health, 2020, 74, jech-2020-213820.	3.7	8
35	Clinical and cost-effectiveness of a diabetes education and behavioural weight management programme versus a diabetes education programme in adults with a recent diagnosis of type 2 diabetes: study protocol for the Glucose Lowering through Weight management (GLoW) randomised controlled trial. BMJ Open, 2020, 10, e035020.	1.9	2
36	Computing the Expected Value of Sample Information Efficiently: Practical Guidance and Recommendations for Four Model-Based Methods. Value in Health, 2020, 23, 734-742.	0.3	51

#	Article	IF	Citations
37	Developing Markov Models From Real-World Data: A Case Study of Heart Failure Modeling Using Administrative Data. Value in Health, 2020, 23, 743-750.	0.3	9
38	Expanding attributable fraction applications to outcomes wholly attributable to a risk factor. Statistical Methods in Medical Research, 2020, 29, 2637-2646.	1.5	9
39	How can health economics be used in the design and analysis of adaptive clinical trials? A qualitative analysis. Trials, 2020, 21, 252.	1.6	4
40	The Normative Underpinnings of Population-Level Alcohol Use: An Individual-Level Simulation Model. Health Education and Behavior, 2020, 47, 224-234.	2.5	14
41	Reweighting national survey data for small area behaviour estimates: modelling alcohol consumption in Local Authorities in England. Population Health Metrics, 2020, 18, 1.	2.7	20
42	Modelling the effects of alcohol pricing policies on alcohol consumption in subpopulations in Australia. Addiction, 2020, 115, 1038-1049.	3.3	17
43	Systematic review and meta‐analysis of randomized controlled trials of psychological interventions to improve glycaemic control in children and adults with type 1 diabetes. Diabetic Medicine, 2020, 37, 735-746.	2.3	25
44	Psychological interventions to improve glycemic control in adults with type 2 diabetes: a systematic review and meta-analysis. BMJ Open Diabetes Research and Care, 2020, 8, e001150.	2.8	19
45	A Software Architecture for Mechanism-Based Social Systems Modelling in Agent-Based Simulation Models. Jasss, 2020, 23, .	1.8	21
46	Evaluating alcohol intoxication management services: the EDARA mixed-methods study. Health Services and Delivery Research, 2020, 8, 1-214.	1.4	4
47	Psychological interventions to improve self-management of type 1 and type 2 diabetes: a systematic review. Health Technology Assessment, 2020, 24, 1-232.	2.8	54
48	Introducing CASCADEPOP: an open-source sociodemographic simulation platform for US health policy appraisal. , 2020, 13, 21-60.		7
49	The impact of promoting revised UK low-risk drinking guidelines on alcohol consumption: interrupted time series analysis. Public Health Research, 2020, 8, 1-108.	1.3	1
50	How should we set consumption thresholds for low risk drinking guidelines? Achieving objectivity and transparency using evidence, expert judgement and pragmatism. Addiction, 2019, 114, 590-600.	3.3	25
51	Toward inverse generative social science using multi-objective genetic programming. , 2019, 2019, 1356-1363.		22
52	PSY1 CONCEPTUALIZING A FRAMEWORK FOR MODELING SYSTEMIC LUPUS ERYTHEMATOSUS. Value in Health, 2019, 22, S374.	0.3	0
53	Modeling the Potential Impact of Changing Access Rates to Specialist Treatment for Alcohol Dependence for Local Authorities in England: The Specialist Treatment for Alcohol Model (STreAM). Journal of Studies on Alcohol and Drugs Supplement, 2019, Sup 18, 96-109.	3.7	12
54	Migraine day frequency in migraine prevention: longitudinal modelling approaches. BMC Medical Research Methodology, 2019, 19, 20.	3.1	8

#	Article	IF	Citations
55	The effects of alcohol pricing policies on consumption, health, social and economic outcomes, and health inequality in Australia: a protocol of an epidemiological modelling study. BMJ Open, 2019, 9, e029918.	1.9	5
56	Examining the relationship between energy poverty and measures of deprivation. Energy Policy, 2019, 130, 206-217.	8.8	32
57	A Review of Clinical Trials With an Adaptive Design and Health Economic Analysis. Value in Health, 2019, 22, 391-398.	0.3	18
58	OP87â€…A comprehensive evaluation of the impact of recent english tobacco control policy using secondary data. , 2019, , .		0
59	Who has access and who participates in parkrun? - implications for selecting future event locations. European Journal of Public Health, 2019, 29, .	0.3	0
60	PDB28 A HEALTH ECONOMIC AND DECISION MODELLING ANALYSIS PLAN FOR AN INTEGRATED DATABASE OF OVER 100 CLINICAL TRIALS MEASURING HYPOGLYCAEMIC ATTACKS FOR PEOPLE WITH DIABETES: A HEDMAP FOR HYPORESOLVE. Value in Health, 2019, 22, S577.	0.3	1
61	Evaluating the impact of individual alcohol licensing decisions on local health and crime: a natural experiment with synthetic controls. Lancet, The, 2019, 394, S35.	13.7	1
62	Mapping alcohol and tobacco tax interventions for health in the UK: a qualitative framework analysis. Lancet, The, 2019, 394, S51.	13.7	0
63	PDB65 PRETRIAL MODELLING METHODS TO JUSTIFY AND INFORM THE DESIGN OF LARGE RCTS - EXPECTED VALUE OF SAMPLE INFORMATION FOR THE DAFNEPLUS DIABETES EDUCATION CLUSTER RCT. Value in Health, 2019, 22, S584.	0.3	0
64	Effects on alcohol consumption of announcing revised UK low-risk drinking guidelines: findings from a monthly cross-sectional survey. Lancet, The, 2019, 394, S54.	13.7	2
65	Cost-effectiveness of strategies to improve delivery of brief interventions for heavy drinking in primary care: results from the ODHIN trial. European Journal of Public Health, 2019, 29, 219-225.	0.3	7
66	Processes of local alcohol policy-making in England: Does the theory of policy transfer provide useful insights into public health decision-making?. Health and Place, 2019, 57, 358-364.	3.3	11
67	Scotland's policy on minimum unit pricing for alcohol: the legal barriers are gone, so what are the implications for implementation and evaluation?. Addiction, 2018, 113, 203-204.	3.3	6
68	Commentary on Apostolopoulos <i>et al</i>. (2018): Systems and complex systems approaches for public health planningâ€"back to the future?. Addiction, 2018, 113, 372-373.	3.3	4
69	Computer Modeling of Diabetes and Its Transparency: A Report on the Eighth Mount Hood Challenge. Value in Health, 2018, 21, 724-731.	0.3	63
70	Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective. Journal of Medical Economics, 2018, 21, 666-675.	2.1	36
71	Modeling the Reduction in the Clinical Burden of Migraine with Erenumab Treatment. Value in Health, 2018, 21, S206.	0.3	0
72	Alcohol Screening and Brief Intervention in Police Custody Suites: Pilot Cluster Randomised Controlled Trial (AcCePT). Alcohol and Alcoholism, 2018, 53, 548-559.	1.6	12

#	Article	IF	Citations
73	How dependent is the alcohol industry on heavy drinking in England?. Addiction, 2018, 113, 2225-2232.	3.3	34
74	Cost-effectiveness of insulin pumps compared with multiple daily injections both provided with structured education for adults with type 1 diabetes: a health economic analysis of the Relative Effectiveness of Pumps over Structured Education (REPOSE) randomised controlled trial. BMJ Open, 2018, 8, e016766.	1.9	27
75	Estimating the cost-effectiveness of brief interventions for heavy drinking in primary health care across Europe. European Journal of Public Health, 2017, 27, ckw122.	0.3	25
76	The impact of Type 2 diabetes prevention programmes based on riskâ€identification and lifestyle intervention intensity strategies: a costâ€effectiveness analysis. Diabetic Medicine, 2017, 34, 632-640.	2.3	29
77	Simulation Modelling in Healthcare: An Umbrella Review of Systematic Literature Reviews. Pharmacoeconomics, 2017, 35, 937-949.	3.3	72
78	Costâ€effectiveness of populationâ€based, community, workplace and individual policies for diabetes prevention in the <scp>UK</scp>. Diabetic Medicine, 2017, 34, 1136-1144.	2.3	30
79	Understanding the alcohol harm paradox: an analysis of sexâ€and conditionâ€specific hospital admissions by socioâ€economic group for alcoholâ€associated conditions in England. Addiction, 2017, 112, 808-817.	3.3	28
80	Assessing the potential return on investment of the proposed UK NHS diabetes prevention programme in different population subgroups: an economic evaluation. BMJ Open, 2017, 7, e014953.	1.9	25
81	The HTA Risk Analysis Chart: Visualising the Need for and Potential Value of Managed Entry Agreements in Health Technology Assessment. Pharmacoeconomics, 2017, 35, 1287-1296.	3.3	38
82	The intervention effect of local alcohol licensing policies on hospital admission and crime: a natural experiment using a novel Bayesian synthetictime-series method. Journal of Epidemiology and Community Health, 2017, 71, 912-918.	3.7	49
83	Discrete Event Simulation-Based Resource Modelling in Health Technology Assessment. Pharmacoeconomics, 2017, 35, 989-1006.	3.3	18
84	Novel Biologics Versus Conventional Preventive Therapies In Migraine: A Framework for Economic Evaluation. Value in Health, 2017, 20, A732.	0.3	2
85	Parametric Modelling of Migraine Day Frequency In Migraine Prevention: A Case Study Of Erenumab Clinical Trial Data. Value in Health, 2017, 20, A733.	0.3	1
86	Expected Value of Sample Information For Individual Level Simulation Models To Inform Stop/Go Decision Making By Public Research Funders: A Methodology for The Dafneplus Diabetes Education Cluster Rct. Value in Health, 2017, 20, A776.	0.3	1
87	Testing the impact of local alcohol licencing policies on reported crime rates in England. Journal of Epidemiology and Community Health, 2017, 71, 137-145.	3.7	39
88	Minimum unit pricing for alcohol clears final legal hurdle in Scotland. BMJ: British Medical Journal, 2017, 359, j5372.	2.3	9
89	Mapping Patterns and Trends in the Spatial Availability of Alcohol Using Low-Level Geographic Data: A Case Study in England 2003â€"2013. International Journal of Environmental Research and Public Health, 2017, 14, 406.	2.6	15
90	Typology and Dynamics of Heavier Drinking Styles in Great Britain: 1978â€"2010. Alcohol and Alcoholism, 2017, 52, 372-381.	1.6	3

#	ARTICLE	IF	CITATIONS
91	A cluster randomised trial, cost-effectiveness analysis and psychosocial evaluation of insulin pump therapy compared with multiple injections during flexible intensive insulin therapy for type 1 diabetes: the REPOSE Trial. Health Technology Assessment, 2017, 21, 1-278.	2.8	42
92	Developing policy analytics for public health strategy and decisions—the Sheffield alcohol policy model framework. Annals of Operations Research, 2016, 236, 149-176.	4.1	15
93	P66…Cross-sectional and longitudinal associations between alcohol licensing policies, outlet density and deprivation and population health and crime in England. Journal of Epidemiology and Community Health, 2016, 70, A83.1-A83.	3.7	0
94	Estimated Effects of Different Alcohol Taxation and Price Policies on Health Inequalities: A Mathematical Modelling Study. PLoS Medicine, 2016, 13, e1001963.	8.4	98
95	An economic evaluation of contingency management for completion of hepatitis B vaccination in those on treatment for opiate dependence. Addiction, 2016, 111, 1616-1627.	3.3	8
96	COST-EFFECTIVENESS OF STRUCTURED EDUCATION IN CHILDREN WITH TYPE-1 DIABETES MELLITUS. International Journal of Technology Assessment in Health Care, 2016, 32, 203-211.	0.5	2
97	A Comprehensive Economic Model for Dementia: Diagnosis, Disease Progression and Service Delivery. Value in Health, 2016, 19, A853.	0.3	0
98	Parametric Simulation of Headache Day Frequency Using A Negative Binomial Distribution: A Case Study of Erenumab in Episodic Migraine. Value in Health, 2016, 19, A361.	0.3	3
99	Modeling the Cost-Effectiveness of Alternative Upper Age Limits for Breast Cancer Screening in England and Wales. Value in Health, 2016, 19, 404-412.	0.3	15
100	Developing a social practice-based typology of British drinking culture in 2009-2011: implications for alcohol policy analysis. Addiction, 2016, 111, 1568-1579.	3.3	85
101	The Impact of Diabetes-Related Complications on Preference-Based Measures of Health-Related Quality of Life in Adults with Type I Diabetes. Medical Decision Making, 2016, 36, 1020-1033.	2.4	42
102	Local policies to tackle a national problem: Comparative qualitative case studies of an English local authority alcohol availability intervention. Health and Place, 2016, 41, 11-18.	3.3	25
103	Comparison of brief interventions in primary care on smoking and excessive alcohol consumption: a population survey in England. British Journal of General Practice, 2016, 66, e1-e9.	1.4	82
104	Are recent attempts to quit smoking associated with reduced drinking in England? A cross-sectional population survey. BMC Public Health, 2016, 16, 535.	2.9	14
105	Temporal patterns of alcohol consumption and attempts to reduce alcohol intake in England. BMC Public Health, 2016, 16, 917.	2.9	22
106	Propensity score matching for selection of local areas as controls for evaluation of effects of alcohol policies in case series and quasi case–control designs. Public Health, 2016, 132, 40-49.	2.9	9
107	Measurable effects of local alcohol licensing policies on population health in England. Journal of Epidemiology and Community Health, 2016, 70, 231-237.	3.7	52
108	A statistical model to describe longitudinal and correlated metabolic risk factors: the Whitehall II prospective study. Journal of Public Health, 2016, 38, 679-687.	1.8	16

#	Article	IF	Citations
109	Deconstructing the Alcohol Harm Paradox: A Population Based Survey of Adults in England. PLoS ONE, 2016, 11, e0160666.	2.5	58
110	The Sheffield Alcohol Policy Model - A Mathematical Description. Health Economics (United Kingdom), 2015, 24, 1368-1388.	1.7	36
111	Valuing Trial Designs from a Pharmaceutical Perspective Using Value-Based Pricing. Health Economics (United Kingdom), 2015, 24, 1468-1482.	1.7	9
112	A theory-based online health behaviour intervention for new university students (U@Uni:LifeGuide): results from a repeat randomized controlled trial. Trials, 2015, 16, 555.	1.6	51
113	The cost-effectiveness of testing strategies for type 2 diabetes: a modelling study. Health Technology Assessment, 2015, 19, 1-80.	2.8	24
114	Estimating the Expected Value of Sample Information Using the Probabilistic Sensitivity Analysis Sample. Medical Decision Making, 2015, 35, 570-583.	2.4	108
115	Protocol for a national monthly survey of alcohol use in England with 6-month follow-up: â€˜The Alcohol Toolkit Studyâ€™. BMC Public Health, 2015, 15, 230.	2.9	49
116	A pilot feasibility trial of alcohol screening and brief intervention in the police custody setting (ACCEPT): study protocol for a cluster randomised controlled trial. Pilot and Feasibility Studies, 2015, 1, 6.	1.2	4
117	Estimating the measurable impact of local alcohol licensing policies on population health in England using ecological longitudinal data. Lancet, The, 2015, 386, S33.	13.7	4
118	Incorporating Psychological Predictors of Treatment Response into Health Economic Simulation Models. Medical Decision Making, 2015, 35, 872-887.	2.4	1
119	An integrated extrapolation of long-term outcomes in systemic lupus erythematosus: analysis and simulation of the Hopkins Lupus Cohort. Rheumatology, 2015, 54, 623-632.	1.9	19
120	Agile Development of an Attitude-Behaviour Driven Simulation of Alcohol Consumption Dynamics. Jasss, 2015, 18, .	1.8	3
121	Evolutionary parameter estimation for a theory of planned behaviour microsimulation of alcohol consumption dynamics in an English birth cohort 2003 to 2010. , 2014, , .		6
122	Potential benefits of minimum unit pricing for alcohol versus a ban on below cost selling in England 2014: modelling study. BMJ, The, 2014, 349, g5452-g5452.	6.0	54
123	Estimating Multiparameter Partial Expected Value of Perfect Information from a Probabilistic Sensitivity Analysis Sample. Medical Decision Making, 2014, 34, 311-326.	2.4	194
124	The impact of spatial and temporal availability of alcohol on its consumption and related harms: A critical review in the context of <scp>UK</scp> licensing policies. Drug and Alcohol Review, 2014, 33, 515-525.	2.1	78
125	Assessing the costâ€effectiveness of TypeÂ1 diabetes interventions: the Sheffield TypeÂ1 Diabetes Policy Model. Diabetic Medicine, 2014, 31, 477-486.	2.3	27
126	Alcohol tax pass-through across the product and price range: do retailers treat cheap alcohol differently?. Addiction, 2014, 109, 1994-2002.	3.3	44

#	Article	IF	Citations
127	Substantial reductions in the number of diabetic ketoacidosis and severe hypoglycaemia episodes requiring emergency treatment lead to reduced costs after structured education in adults with Type 1 diabetes. Diabetic Medicine, 2014, 31, 847-853.	2.3	90
128	The cost-effectiveness of a theory-based online health behaviour intervention for new university students: an economic evaluation. BMC Public Health, 2014, 14, 1011.	2.9	11
129	Trend analysis and modelling of gender-specific age, period and birth cohort effects on alcohol abstention and consumption level for drinkers in <scp>G</scp>reat <scp>B</scp>ritain using the <scp>G</scp>eneral <scp>L</scp>ifestyle <scp>S</scp>urvey 1984–2009. Addiction, 2014, 109, 206-215.	3.3	107
130	Reporting the characteristics of the policy context for population-level alcohol interventions: A proposed 'Transparent Reporting of Alcohol Intervention ContExts' (TRAICE) checklist. Drug and Alcohol Review, 2014, 33, 596-603.	2.1	4
131	Cost-effectiveness of a programme of screening and brief interventions for alcohol in primary care in Italy. BMC Family Practice, 2014, 15, 26.	2.9	28
132	Modelling the Economics of Type 2 Diabetes Mellitus Prevention: A Literature Review of Methods. Applied Health Economics and Health Policy, 2014, 12, 239-253.	2.1	17
133	Estimation of usual occasion-based individual drinking patterns using diary survey data. Drug and Alcohol Dependence, 2014, 134, 136-143.	3.2	9
134	Investigating local policy drivers for alcohol harm prevention: a comparative case study of two local authorities in England. Lancet, The, 2014, 384, S52.	13.7	1
135	Choosing between different alcohol pricing and taxation strategies: a comparative policy appraisal using the Sheffield Alcohol Policy Model. Lancet, The, 2014, 384, S51.	13.7	0
136	Layering Interventions for Type-2 Diabetes Prevention Using The Sphr Diabetes Model. Value in Health, 2014, 17, A347.	0.3	2
137	A theory-based online health behaviour intervention for new university students (U@Uni): results from a randomised controlled trial. BMC Public Health, 2014, 14, 563.	2.9	71
138	Effects of minimum unit pricing for alcohol on different income and socioeconomic groups: a modelling study. Lancet, The, 2014, 383, 1655-1664.	13.7	235
139	Estimation of own and cross price elasticities of alcohol demand in the UK—A pseudo-panel approach using the Living Costs and Food Survey 2001–2009. Journal of Health Economics, 2014, 34, 96-103.	2.7	68
140	Improving management of type 1 diabetes in the UK: the Dose Adjustment For Normal Eating (DAFNE) programme as a research test-bed. A mixed-method analysis of the barriers to and facilitators of successful diabetes self-management, a health economic analysis, a cluster randomised controlled trial of different models of delivery of an educational intervention and the potential of insulin pumps and additional educator input to improve outcomes. Programme Grants for Applied Research, 2014, 2, 1-188.	1.0	28
141	A theory-based online health behavior intervention for new university students: study protocol. BMC Public Health, 2013, 13, 107.	2.9	23
142	Innovation in health economic modelling of service improvements for longer-term depression: demonstration in a local health community. BMC Health Services Research, 2013, 13, 150.	2.2	10
143	The cost of Type 1 diabetes mellitus in the United Kingdom: a review of cost-of-illness studies. European Journal of Health Economics, 2013, 14, 887-899.	2.8	4
144	The expected value of sample information from the pharmaceutical perspective under conditions of value based pricing. Value in Health, 2013, 16, A29.	0.3	0

#	ARTICLE	IF	CITATIONS
145	Telemonitoring After Discharge from Hospital with Heart Failure â€" Cost-Effectiveness Modelling of Alternative Service Designs. Value in Health, 2013, 16, A530.	0.3	4
146	Minimum unit pricing for alcohol: policy appraisal modelling of income and socioeconomic group-specific effects on consumption, spending, and health harms. Lancet, The, 2013, 382, S47.	13.7	1
147	The canard project (projet canard) cost-effectiveness analysis of real-world outcomes in a diabetic population: The impact of baseline characteristics in France. Value in Health, 2013, 16, A284.	0.3	0
148	Cost-effectiveness modelling of telemonitoring after discharge from hospital with heart failure. Value in Health, 2013, 16, A290.	0.3	2
149	Using Whole Disease Modeling to Inform Resource Allocation Decisions: Economic Evaluation of a Clinical Guideline for Colorectal Cancer Using a Single Model. Value in Health, 2013, 16, 542-553.	0.3	20
150	Adjusting for Unrecorded Consumption in Survey and per Capita Sales Data: Quantification of Impact on Gender- and Age-specific Alcohol-attributable Fractions for Oral and Pharyngeal Cancers in Great Britain. Alcohol and Alcoholism, 2013, 48, 241-249.	1.6	41
151	Does an intensive self-management structured education course improve outcomes for children and young people with type 1 diabetes? The Kids In Control OF Food (KICk-OFF) cluster-randomised controlled trial protocol: TableÂ1. BMJ Open, 2013, 3, e002429.	1.9	12
152	Telemonitoring after discharge from hospital with heart failure: cost-effectiveness modelling of alternative service designs. BMJ Open, 2013, 3, e003250.	1.9	41
153	Modelling the Cost-Effectiveness of Alcohol Screening and Brief Interventions in Primary Care in England. Alcohol and Alcoholism, 2013, 48, 180-188.	1.6	58
154	The costâ€effectiveness of the Dose Adjustment for Normal Eating (<scp>DAFNE</scp>) structured education programme: an update using the Sheffield TypeÂ1 Diabetes Policy Model. Diabetic Medicine, 2013, 30, 1236-1244.	2.3	37
155	Home telemonitoring or structured telephone support programmes after recent discharge in patients with heart failure: systematic review and economic evaluation. Health Technology Assessment, 2013, 17, 1-207, v-vi.	2.8	100
156	Financial modelling for telemonitoring. International Journal of Integrated Care, 2013, 13, .	0.2	0
157	Whole Disease Modeling to Inform Resource Allocation Decisions in Cancer: A Methodological Framework. Value in Health, 2012, 15, 1127-1136.	0.3	43
158	Modeling Using Discrete Event Simulation. Medical Decision Making, 2012, 32, 701-711.	2.4	189
159	The temporal relationship between per capita alcohol consumption and harm: A systematic review of time lag specifications in aggregate time series analyses. Drug and Alcohol Dependence, 2012, 123, 7-14.	3.2	84
160	PDB111 Accounting for Psychological Determinants of Treatment Response in Health Economic Simulation Models of Behavioural Interventions: A Case Study in Type 1 Diabetes. Value in Health, 2012, 15, A191.	0.3	1
161	PDB62 Cost-Effectiveness Modelling of Type-1 Diabetes. Value in Health, 2012, 15, A181-A182.	0.3	0
162	Modeling using Discrete Event Simulation: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-4. Value in Health, 2012, 15, 821-827.	0.3	166

#	Article	IF	Citations
163	Non-pharmacological interventions to reduce the risk of diabetes in people with impaired glucose regulation: a systematic review and economic evaluation.. Health Technology Assessment, 2012, 16, 1-236, iii-iv.	2.8	98
164	Estimating Expected Value of Sample Information for Incomplete Data Models Using Bayesian Approximation. Medical Decision Making, 2011, 31, 839-852.	2.4	14
165	MO3 A Methodological Framework for Developing Models of Whole Disease Areas to Inform Resource Allocation Decisions. Value in Health, 2011, 14, A243.	0.3	6
166	PCN193 Using Whole Disease Modelling to Inform Economic Recommendations for the Detection, Diagnosis, Treatment and Follow-up of Colorectal Cancer. Value in Health, 2011, 14, A469-A470.	0.3	2
167	O4-6.4 The development of models to underpin public health guidance. Journal of Epidemiology and Community Health, 2011, 65, A47-A47.	3.7	0
168	Assessing the cost-effectiveness of the rivastigmine transdermal patch for Alzheimer's disease in the UK using MMSE- and ADL-based models. International Journal of Geriatric Psychiatry, 2011, 26, 483-494.	2.7	15
169	The Sheffield rheumatoid arthritis health economic model. Rheumatology, 2011, 50, iv26-iv31.	1.9	19
170	Policy options for alcohol price regulation: the importance of modelling population heterogeneity. Addiction, 2010, 105, 383-393.	3.3	154
171	POLICY OPTIONS FOR ALCOHOL PRICE REGULATION: RESPONSE TO THE COMMENTARIES. Addiction, 2010, 105, 400-401.	3.3	1
172	Decision Modeling to Inform Decision Making: Seeing the Wood for the Trees. Medical Decision Making, 2010, 30, E20-E22.	2.4	4
173	Delivering the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cost effectiveness analysis. BMJ: British Medical Journal, 2010, 341, c4093-c4093.	2.3	168
174	A cost-utility analysis of clopidogrel in patients with ST elevation acute coronary syndromes in the UK. International Journal of Cardiology, 2010, 140, 315-322.	1.7	10
175	Simulation sample sizes for Monte Carlo partial EVPI calculations. Journal of Health Economics, 2010, 29, 468-477.	2.7	49
176	PDB26 MODELLING COST EFFECTIVENESS OF BEHAVIOUR MODIFICATION PROGRAMMES AND EFFECTS ON MEDICATION: CASE STUDY OF EDUCATION PROGRAMMES IN DIABETES. Value in Health, 2010, 13, A59.	0.3	0
177	Estimated effect of alcohol pricing policies on health and health economic outcomes in England: an epidemiological model. Lancet, The, 2010, 375, 1355-1364.	13.7	208
178	The Cost-Effectiveness of an RCT to Establish Whether 5 or 10 Years of Bisphosphonate Treatment Is the Better Duration for Women With a Prior Fracture. Medical Decision Making, 2009, 29, 678-689.	2.4	19
179	Using short-term evidence to predict six-month outcomes in clinical trials of signs and symptoms in rheumatoid arthritis. Pharmaceutical Statistics, 2009, 8, 150-162.	1.3	8
180	The Rheumatoid Arthritis Drug Development Model: a case study in Bayesian clinical trial simulation. Pharmaceutical Statistics, 2009, 8, 371-389.	1.3	16

#	Article	IF	Citations
181	Systematic review of economic evidence for the detection, diagnosis, treatment, and follow-up of colorectal cancer in the United Kingdom. International Journal of Technology Assessment in Health Care, 2009, 25, 470-478.	0.5	16
182	Biologic drugs for rheumatoid arthritis in the medicare program: A cost–effectiveness analysis. Arthritis and Rheumatism, 2008, 58, 939-946.	6.7	82
183	Modelling the cost-effectiveness and capacity impact of changes to colposcopy referral guidelines for women with mild dyskaryosis in the UK Cervical Screening Programme. BJOG: an International Journal of Obstetrics and Gynaecology, 2008, 115, 749-757.	2.3	3
184	Cost-Effectiveness and Value of Information Analyses of Neuraminidase Inhibitors for the Treatment of Influenza. Value in Health, 2008, 11, 160-171.	0.3	19
185	PDB19 ESTIMATING THE COST EFFECTIVENESS IN THE UK OF VILDAGLIPTIN COMPARED TO PIOGLITAZONE AS ADD-ON THERAPY TO METFORMIN USING THE SHEFFIELD TYPE 2 DIABETES MODEL. Value in Health, 2008, 11, A501.	0.3	1
186	PCV30 CLOPIDOGREL IS COST-EFFECTIVE COMPARED WITH ASPIRIN IN UNITED KINGDOM PATIENTS WITH A MYOCARDIAL INFARCTION WHO SUBSEQUENTLY SUSTAIN AN ISCHAEMIC STROKE OR PERIPHERAL ARTERIAL DISEASE EVENT. Value in Health, 2008, 11, A194-A195.	0.3	0
187	Comment on: Modelling the cost effectiveness of TNF-Â antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry: reply. Rheumatology, 2008, 47, 1107-1107.	1.9	0
188	Calculating Partial Expected Value of Perfect Information via Monte Carlo Sampling Algorithms. Medical Decision Making, 2007, 27, 448-470.	2.4	103
189	Modelling the cost effectiveness of TNF-Â antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry. Rheumatology, 2007, 46, 1345-1354.	1.9	111
190	The efficacy of inhibiting tumour necrosis factor Â and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons. Rheumatology, 2007, 46, 1140-1147.	1.9	96
191	Efficient computation of partial expected value of sample information using Bayesian approximation. Journal of Health Economics, 2007, 26, 122-148.	2.7	48
192	PAR15 USING MIXED TREATMENT COMPARISONS AND METAREGRESSION TO PERFORM INDIRECT COMPARISONS TO ESTIMATE THE EFFICACY OF BIOLOGIC TREATMENTS IN RHEUMATOID ARTHRITIS. Value in Health, 2007, 10, A121.	0.3	2
193	A Critique and Impact Analysis of Decision Modeling Assumptions. Medical Decision Making, 2007, 27, 491-499.	2.4	18
194	PND15 THE COST-UTILITY OF EXELON PATCH IN THE MANAGEMENT OF PATIENTS WITH MODERATE ALZHEIMER'S DISEASE IN THE UNITED KINGDOM. Value in Health, 2007, 10, A384.	0.3	1
195	Expected value of sample information for Weibull survival data. Health Economics (United Kingdom), 2007, 16, 1205-1225.	1.7	24
196	Using mixed treatment comparisons and meta–regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis. Statistics in Medicine, 2007, 26, 1237-1254.	1.6	125
197	The cost-effectiveness of sibutramine in non-diabetic obese patients: evidence from four Western countries. Obesity Reviews, 2007, 8, 363-371.	6.5	15
198	The Cost-Effectiveness of Lanthanum Carbonate in the Treatment of Hyperphosphatemia in Patients with End-Stage Renal Disease. Value in Health, 2007, 10, 32-41.	0.3	30

#	ARTICLE	IF	CITATIONS
199	Screening for type 2 diabetes: literature review and economic modelling. Health Technology Assessment, 2007, 11, iii-iv, ix-xi, 1-125.	2.8	224
200	A cost-utility analysis of clopidogrel in patients with non-ST-segment-elevation acute coronary syndromes in the UK. International Journal of Cardiology, 2006, 109, 307-316.	1.7	25
201	Assessment of clinical and economic benefits of weight management with sibutramine in general practice in Germany. European Journal of Health Economics, 2006, 7, 276-284.	2.8	12
202	A taxonomy of model structures for economic evaluation of health technologies. Health Economics (United Kingdom), 2006, 15, 1295-1310.	1.7	429
203	Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis. Rheumatology, 2006, 45, 1029-1038.	1.9	42
204	Can we use routine data to evaluate organizational change? Lessons from the evaluation of business process re-engineering in a UK teaching hospital. Health Services Management Research, 2005, 18, 265-276.	1.7	12
205	The NICE reappraisal of biologics in 2005: what rheumatologists need to know. British Journal of Rheumatology, 2005, 44, 3-4.	2.3	16
206	A pharmacoeconomic review of adalimumab in the treatment of rheumatoid arthritis. Expert Review of Pharmacoeconomics and Outcomes Research, 2005, 5, 519-529.	1.4	6
207	Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden. Annals of the Rheumatic Diseases, 2005, 64, 995-1002.	0.9	101
208	Modelling the long term cost effectiveness of clopidogrel for the secondary prevention of occlusive vascular events in the UK. Current Medical Research and Opinion, 2005, 21, 101-112.	1.9	36
209	Incorporation of uncertainty in health economic modelling studies. Pharmacoeconomics, 2005, 23, 529-536.	3.3	49
210	Should Patients Have a Greater Role in Valuing Health States?. Applied Health Economics and Health Policy, 2005, 4, 201-208.	2.1	139
211	An Overview of Economic Evaluations for Drugs Used in Rheumatoid Arthritis. Drugs, 2005, 65, 473-496.	10.9	65
212	Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. British Journal of Rheumatology, 2004, 43, 62-72.	2.3	142
213	Cost-Effectiveness of Sibutramine in the Treatment of Obesity. Medical Decision Making, 2004, 24, 9-19.	2.4	35
214	Re: Wolfe et al. Do rheumatology cost-effectiveness analyses make sense?. British Journal of Rheumatology, 2004, 43, 677-678.	2.3	6
215	PAR5 COST-EFFECTIVENESS OF ADALIMUMAB (HUMIRATM) IN THE TREATMENT OF US PATIENTS WITH RHEUMATOID ARTHRITIS (RA). Value in Health, 2004, 7, 241.	0.3	1
216	PUK23 LANTHANUM CARBONATE FOR THE TREATMENT OF HYPERPHOSPHATAEMIA: DEVELOPMENT OF A COSTEFFECTIVENESS MODEL. Value in Health, 2004, 7, 805.	0.3	0

#	Article	IF	Citations
217	Commentary on Coyle et al., "The assessment of the economic return from controlled clinical trials". European Journal of Health Economics, 2003, 4, 239-240.	2.8	1
218	Evaluation of the Impact of a Technology Appraisal Process in England: The South and West Development and Evaluation Committee. Journal of Health Services Research and Policy, 2003, 8, 18-24.	1.7	7
219	Evaluation of the impact of a technology appraisal process in England: the South and West Development and Evaluation Committee. Journal of Health Services Research and Policy, 2003, 8, 18-24.	1.7	5
220	The role of modelling in prioritising and planning clinical trials. Health Technology Assessment, 2003, 7, iii, 1-125.	2.8	63
221	Estimating the potential health gain and cost consequences of introducing a pre-school DTPa pertussis booster into the UK child vaccination schedule. Vaccine, 2002, 20, 1778-1786.	3.8	22
222	Triaging patients with serious head injury: results of a simulation evaluating strategies to bypass hospitals without neurosurgical facilities. Injury, 2001, 32, 267-274.	1.7	13
223	Is it feasible to plan secondary care services for coronary heart disease rationally? A quantified modelling approach for a UK Health Authority. Journal of Epidemiology and Community Health, 2001, 55, 521-527.	3.7	4
224	Modelling in Health Economic Evaluation. Pharmacoeconomics, 2000, 17, 445-459.	3.3	113
225	The cost-effectiveness of the KIds in control of food structured education programme for adolescents with type 1 diabetes. Endocrine Abstracts, 0, , .	0.0	0
226	Systematic Review and Meta-Analysis of Randomised Controlled Trials of Psychological Interventions to Improve Glycaemic Control in Adults with Type 2 Diabetes. SSRN Electronic Journal, 0, , .	0.4	1
227	Estimating the impact of changes in weight and BMI on EQ-5D-3L: a longitudinal analysis of a behavioural group-based weight loss intervention. Quality of Life Research, 0, , .	3.1	0